lamivudine has been researched along with Chronic Liver Failure in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, A; Cheung, TT; Chok, K; Dai, WC; Fung, J; Lai, CL; Lo, CM; Man, K; Ng, K; Seto, WK; Sin, SL; Wong, T; Yuen, MF | 1 |
| Chun, JM; Han, YS; Hur, K; Jang, SY; Kang, MK; Kweon, YO; Lee, HJ; Lee, HW; Lee, YR; Park, JG; Park, SY; Tak, WY | 1 |
| Jiang, B; Li, L; Li, ZF; Song, SB; Xiu, DR; Yuan, CH; Zhang, TL | 1 |
| Gan, WQ; Ke, WM; Lai, J; Mai, L; Yan, Y; Zheng, YB | 1 |
| Gao, YJ; Jin, B; Li, HW; Liu, ZW; Ma, XM; Meng, FP; Su, HB; Zhang, M; Zhao, JM | 1 |
| Chang, JY; Chen, CH; Chien, RN; Hu, TH; Hung, CH; Lee, CM; Lin, CL; Lu, SN; Tseng, PL; Wang, JH | 1 |
| Shouval, D | 1 |
| Cheng, L; Geng, L; Wang, W; Wu, L; Yan, S; Ye, Y; Yu, J; Yu, S; Yu, Z; Zhang, W; Zheng, S | 1 |
| Buti, M; Casafont, F; Casillas, R; Castells, L; Esteban, R; González, A; Herrero, JI; Homs, M; Mas, A; Miras, M; Prieto, M; Rodríguez-Frías, F; Tabernero, D | 1 |
| Akarca, US; Bademkiran, F; Duman, S; Ersoz, G; Gunsar, F; Karasu, Z; Kose, T; Ozutemiz, O; Sozbilen, M; Turan, I; Yapali, S | 1 |
| Gao, F; Geng, M; Jiang, Y; Li, A; Li, X; Li, Y; Liu, H; Liu, Y; Sun, L; Wang, R; Wang, X; Yang, Z; Ye, X; Zeng, H; Zhang, H; Zhou, G | 1 |
| Chen, J; Chen, JM; Ding, JB; Du, N; Duan, XZ; He, WP; Hu, JH; Huang, K; Liu, XY; Wang, HF | 1 |
| Cao, H; Chen, LB; Chen, N; Li, G; Shu, X; Xu, QH; Zhang, K; Zhang, YF | 1 |
| Chen, T; He, Y; Liu, H; Liu, X; Wang, K; Yan, Z; Zhang, S; Zhao, Y | 1 |
| Wang, H; Yang, J; Zhu, X | 1 |
4 trial(s) available for lamivudine and Chronic Liver Failure
| Article | Year |
|---|---|
Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.
Topics: Acute-On-Chronic Liver Failure; Adult; Antiviral Agents; Drug Resistance, Viral; End Stage Liver Disease; Female; Follow-Up Studies; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Polymorphism, Restriction Fragment Length; Predictive Value of Tests; Prognosis; Severity of Illness Index | 2014 |
Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
Topics: DNA, Viral; End Stage Liver Disease; Evolution, Molecular; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoglobulins; Lamivudine; Liver Transplantation; Male; Middle Aged; Reverse Transcriptase Inhibitors; Secondary Prevention; Sequence Analysis, DNA; Treatment Outcome | 2015 |
[Efficacy of antiviral treatment on patients with acute-on-chronic hepatitis B liver failure with low viral load].
Topics: Adult; Antiviral Agents; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Male; Middle Aged; Nucleosides; Pyrimidinones; Telbivudine; Thymidine; Viral Load | 2010 |
[Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis].
Topics: Adenine; Adult; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis B, Chronic; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Organophosphonates | 2012 |
11 other study(ies) available for lamivudine and Chronic Liver Failure
| Article | Year |
|---|---|
Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; End Stage Liver Disease; Female; Genotype; Graft Survival; Hepatitis B virus; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Liver Transplantation; Male; Middle Aged; Mutation; Nucleosides; Nucleotides; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Virus Activation | 2017 |
Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
Topics: Adult; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Republic of Korea; ROC Curve; Severity of Illness Index; Tenofovir; Treatment Outcome | 2018 |
HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; DNA, Viral; End Stage Liver Disease; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Secondary Prevention; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure.
Topics: Administration, Oral; Adult; Analysis of Variance; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Failure, Acute; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.
Topics: Adult; Age Factors; Antiviral Agents; Aspartic Acid; Carcinoma, Hepatocellular; China; DNA, Viral; Drug Therapy, Combination; End Stage Liver Disease; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Immunoglobulins; Lamivudine; Liver Neoplasms; Liver Transplantation; Male; Methionine; Middle Aged; Mutation; Retrospective Studies; Risk Factors; Secondary Prevention; Sex Factors; Tyrosine | 2014 |
The pros and cons of lamivudine vs. entecavir in decompensated or severe acute exacerbation of chronic hepatitis B.
Topics: Acute-On-Chronic Liver Failure; End Stage Liver Disease; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male | 2014 |
Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation.
Topics: Adult; Antiviral Agents; China; Donor Selection; End Stage Liver Disease; Female; Graft Survival; Hepatitis B; Hepatitis B Surface Antigens; Humans; Immunization, Passive; Immunoglobulins; Lamivudine; Liver; Liver Transplantation; Male; Middle Aged; Patient Safety; Retrospective Studies; Seroepidemiologic Studies; Tissue Donors; Transplants; Treatment Outcome | 2014 |
Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy.
Topics: Aged; Antiviral Agents; Diabetes Mellitus; Drug Substitution; End Stage Liver Disease; Female; Glomerular Filtration Rate; Hepatitis B; Humans; Incidence; Kaplan-Meier Estimate; Kidney; Lamivudine; Liver Transplantation; Male; Middle Aged; Muscular Diseases; Polyneuropathies; Proportional Hazards Models; Prospective Studies; Recovery of Function; Recurrence; Renal Insufficiency, Chronic; Risk Factors; Telbivudine; Thymidine; Time Factors; Treatment Outcome; Turkey | 2015 |
Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score.
Topics: Acute-On-Chronic Liver Failure; Adult; Antiviral Agents; Decision Support Techniques; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B, Chronic; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
[Lamivudine and entecavir significantly improved the prognosis of early-to-mid stage hepatitis B related acute on chronic liver failure].
Topics: Anti-HIV Agents; Disease Susceptibility; End Stage Liver Disease; Guanine; Humans; Lamivudine; Prognosis | 2010 |
Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; End Stage Liver Disease; Female; Follow-Up Studies; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Prognosis; Retrospective Studies; Secondary Prevention; Time Factors; Treatment Outcome; Young Adult | 2012 |